Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A capsule with a marketed drug, fenofibrate, in Chinese patients with moderate dyslipidemia.


Clinical Trial Description

Although lowering cholesterol and low-density lipoprotein-cholesterol (LDL-C) is the mainstay of medical therapy for cardiovascular event prevention, evidence from clinical trials supports a role for elevated triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) concentrations in the residual cardiovascular risk on statin treatment. Fenofibrate is the most commonly used agent to control hypertriglyceridemia as monotherapy or combining with statin, which lowers TG and raises HDL-C through multifaceted mechanism by PPARĪ± activation. However, safety of coadministration of statin with fenofibrate has been a great concern, especially drug-induced hepatotoxicity when they are combined used. Coenzyme A (CoA) functions as an acyl group carrier and assists in transferring fatty acids from the cytoplasm to mitochondria. It is also involved in the oxidation and catabolism of fatty acids. Animal studies have proved its lipid-lowering effects. In a previous multicenter study we conducted in 2008, it was found that oral CoA 400U/d effectively lowered serum TG levels in hypertriglyceridemia patients without increasing adverse effects when compared with placebo. So, the present study was performed to further investigate the lipid-lowing effects and safety of CoA capsule by comparing with fenofibrate. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01878227
Study type Interventional
Source Zhejiang University
Contact
Status Completed
Phase Phase 3
Start date July 2010
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT00000538 - Dietary Effects on Lipoproteins and Thrombogenic Activity Phase 3
Completed NCT01645046 - The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia Phase 2
Completed NCT01146522 - Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia Phase 1/Phase 2
Recruiting NCT01928342 - The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia Phase 2/Phase 3
Terminated NCT01239992 - Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia Phase 4
Completed NCT02933138 - Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia N/A
Completed NCT01811082 - Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia Phase 3
Active, not recruiting NCT05256654 - A Study of LY3561774 in Participants With Mixed Dyslipidemia Phase 2
Completed NCT00005128 - Lipid Research Clinics Population Studies N/A
Completed NCT01057654 - A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin Phase 3
Completed NCT00001226 - Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins N/A